Melanoma progression is associated with the expression of different growth factors, cytokines, and chemokines. Because TGFb1 is a pleiotropic cytokine involved not only in physiologic processes but also in cancer development, we analyzed in A375 human melanoma cells, the effect of TGFb1 on monocyte chemoattractant protein-1 (MCP-1) and interleukin-10 (IL-10) expression, two known factors responsible for melanoma progression. TGFb1 increased the expression of MCP-1 and IL-10 in A375 cells, an effect mediated by the cross-talk between Smad, PI3K (phosphoinositide 3-kinase)/AKT, and BRAF-MAPK (mitogen activated protein kinase) signaling pathways. Supernatants from TGFb1-treated A375 cells enhanced MCP-1-dependent migration of monocytes, which, in turn, expressed high levels of TGF,b1, bFGF, and VEGF mRNA. Moreover, these supernatants also inhibited functional properties of dendritic cells through IL-10-dependent mechanisms. When using in vitro, the TGFb1-blocking peptide P144, TGFb1-dependent Smad3 phosphorylation, and expression of MCP-1 and IL-10 were inhibited. In vivo, treatment of A375 tumor-bearing athymic mice with P144 significantly reduced tumor growth, associated with a lower macrophage infiltrate and decreased intratumor MCP-1 and VEGF levels, as well as angiogenesis. Finally, in C57BL/6 mice with B16-OVA melanoma tumors, when administered with immunotherapy, P144 decreased tumor growth and intratumor IL-10 levels, linked to enhanced activation of dendritic cells and natural killer cells, as well as anti-OVA T-cell responses. These results show new effects of TGFb1 on melanoma cells, which promote tumor progression and immunosuppression, strongly reinforcing the relevance of this cytokine as a molecular target in melanoma.
Introduction
TGFb1 is a pleiotropic cytokine that plays a relevant role in the progression of cancer due to its effect on cell proliferation, angiogenesis, epithelial-to-mesenchymal transition, and metastasis (1) . Also, it has been described that TGFb1 induces the expression of integrins and alters the composition of extracellular matrix by activating the production of matrix metalloproteinases, which favor the invasion of tumor cells. Moreover, TGFb1 enhances angiogenesis by activating the expression of proangiogenic factors such as interleukin (IL)-8 and VEGF (2) . This molecule also exerts immunoregulatory functions by inhibiting proliferation, activation, and differentiation of lymphocytes (3) as well as the function of natural killer (NK) cells (4) and dendritic cells (DC; ref. 5) , which leads to the suppression of the antitumor immune response.
TGFb1 has been described as an important factor in the development of melanoma. Although it has antiproliferative effects on premalignant cells, as that occurs in normal melanocytes, advanced melanoma cells become resistant to this suppressive effect and they can use TGFb1 to enhance their invasive and metastatic phenotype (6) . Tumor cells evade the suppressive effect of TGFb1 through receptor-or Smad-inactivating mutations (7, 8) or by downstream signaling alterations. These modifications avoid the suppressive pathway and induce prometastatic processes (9) . Although no genetic mutations of TGFb1 classical signaling molecules have been identified in melanoma, a cross-talk between the Smad signaling pathway and other pathways, including Ras/MEK [MAP/ extracellular signal regulated kinase (ERK) kinase]/ERK, and Akt, which are constitutively activated in a large percentage of cutaneous melanomas, has been described (2, 10) .
The majority of malignant melanoma cells overexpress different growth factors and cytokines, which enhance growth rate and invasiveness by their autocrine and paracrine effects (11) . Monocyte chemoattractant protein-1 (MCP-1), a potent chemokine that recruits macrophages, is expressed by malignant but not by normal melanocytes (12) . Accordingly, a common feature of melanoma is the infiltration of monocyte/macrophages. These cells produce factors, which may help tumor invasion, as well as the production of angiogenic factors, which facilitate the formation of a vascular bed that can support tumor development (13) . Another factor common in melanoma is IL-10. Its expression has been shown in vitro in many melanoma cell lines (14) , and in vivo, in primary and in metastatic melanoma lesions (15) . Moreover, elevated levels of IL-10 have been observed in the sera of patients with advanced melanoma and correlate with tumor progression (16) .
Because TGFb1 has been shown to increase melanoma progression and enhance its aggressive phenotype, due to the important effects of MCP-1 and IL-10 have on melanoma malignancy, we hypothesized that TGFb1 might play a role on the expression of these molecules in melanoma cells. Thus, we studied the effect of TGFb1 on A375 melanoma cells by measuring the expression of MCP-1 and IL-10 as well as the consequences that expression of these factors had on melanoma progression. Moreover, the signaling pathways involved in the TGFb1-induced MCP-1 and IL-10 expression were also studied. Finally, as described in more detail in the following text, we showed that P144, a peptide inhibitor of TGFb1, had beneficial effects in vitro and in vivo, by inhibiting TGFb1-induced mechanisms associated with melanoma development and immunosuppression.
Materials and Methods

Cell lines
Cell lines A375 and YAC-1 were obtained from American Type Culture Collection (ATCC). Cells were thawed and passaged according to ATCC guidelines for less than 6 months from the time that they were received or thawed. The ATCC authenticates cell lines by DNA fingerprinting by short tandem repeat analysis. B16-OVA cells were obtained from Dr. G. Kroemer (Paris, France) in 2009. No authentication was done, but the expression of OVA antigen and MHC-I molecules was tested before the experiments. Cell lines were maintained in DMEM (Gibco) supplemented with 10% heat-inactivated FBS (Gibco), 100 units/mL penicillin, and 100 mg/mL streptomycin (Gibco), 1.5 g/L sodium bicarbonate (Sigma), and 4.5 g/L glucose (Sigma).
Stimulation of A375 cells with TGFb1
A375 cells were cultured in 96-well plates (3 Â 10 4 per well) and stimulated with TGFb1 (R&D Systems; 1 ng/mL) in DMEM supplemented with 10% FBS and antibiotics. After 24 to 48 hours, supernatants were harvested to measure MCP-1 and IL-10. In some experiments, TGFb1 was preincubated at 37 C for 1 hour with anti-human TGFb1 (1 mg/mL), rat IgG control isotype (BD-Pharmingen), the TGFb1 inhibitor peptide P144 (50-200 mg/mL; ref. 17) or a control 15-mer peptide (P301; NNTRKRIRIQRGPGR) that does not bind to TGFb1 (both from NeoMPS). To determine the signaling pathways involved in the production of MCP-1 and IL-10 by A375 cells, Smad3 inhibitor SIS3 (Calbiochem), mitogen activated protein kinase (MAPK)/ERK1/2 inhibitor U0126 (Promega), phosphatidylinositol 3-kinase (PI3K)-specific inhibitor LY294002 (Calbiochem), all at 10 mmol/L, or DMSO were preincubated with A375 cells 30 minutes before the addition of TGFb1. Expression of phosphorylated forms of Smad3, AKT, and ERK1/2 induced by TGFb1 (2 ng/mL) was assessed by Western blotting in A375 lysates from cells cultured in 6-well plates (3 Â 10 5 per well) in serum-free DMEM for 1 hour. In some experiments, TGFb1 was preincubated at 37 C for 1 hour with P144 or control peptide (50-200 mg/mL).
Generation of melanoma conditioned medium from stimulated A375 cells
Melanoma conditioned media from A375 cells treated with or without TGFb1 (TGFb-MCM and MCM, respectively) used in functional in vitro experiments with monocytes and monocyte-derived DCs were produced by culturing A375 cells in 6-well plates (2.5 Â 10 5 per well) in DMEM with or without TGFb1 (2 ng/mL) for 24 hours. Then, cells were washed twice with medium to remove TGFb1 and maintained in culture for an additional 48 hours.
Western blot analysis
One hour after cell stimulation with TGFb1 as described earlier, cells were washed with PBS, lysed with RIPA (radioimmunoprecipitation assay) buffer in the presence of protease and phosphatase inhibitors (Roche Diagnostic GmbH), and precipitated proteins (30 mg) were resolved on 10% SDSpolyacrylamide gels. After transference onto nitrocellulose membranes (Bio-Rad), nonspecific binding was blocked with 10% nonfat milk in 10 mmol/L Tris-buffered saline containing 0.1% Tween 20. Phosphorylated Smad3, AKT, and ERK1/2 were detected using rabbit polyclonal antibodies anti-phospho Smad3 (1:1,000; Chemicon), AKT (1:1,000; Cell Signaling), and MAP kinase 1/2 (ERK1/2; 1:1,000; Cell Signaling). Actin was also analyzed for control evaluation with rabbit anti-actin (1:2,000; Sigma-Aldrich) antibodies. Finally, an ECL anti-rabbit IgG linked to horseradish peroxidase (Amersham Biosciences) plus the Lumi-Light Western Blotting Substrate (Roche Diagnostic GmbH) was used to develop the proteins bands in films scanned with the Curix-60 (AGFA).
Monocyte migration assay
Monocytes were obtained from peripheral blood mononuclear cells by positive selection with CD14-coated beads (Miltenyi). In all cases, peripheral blood mononuclear cells were obtained from healthy donors after informed consent, following a protocol in accordance with the Declaration of Helsinki. Then, monocytes (5 Â 10 5 ) were plated in 100 mL of complete medium (RPMI 1640 supplemented with 10% heatinactivated FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin) in the top chamber of 5-mm pore membrane Transwells (Costar), with 5 mg/mL rat anti-human MCP-1 antibody (R&D Systems) or rat IgG control isotype (BD-Pharmingen) when required. The bottom chamber was filled with 500 mL of DMEM, MCM, or TGFb1-MCM. In some cases, melanoma conditioned media were incubated with anti-human MCP-1 antibody or rat IgG for 1 hour at 37 C prior to the addition of media to Transwell plates. After 4 hours, the number of monocytes in the lower chamber was counted by flow cytometry as described (18) .
Culture of DCs in TGFb1-MCM
Monocyte-derived DCs obtained as described (18) were cultured in 96-well plates (10 5 in 200 mL per well) in RPMI with DMEM, MCM, or TGFb1-MCM (proportion 4:1) for 6 hours. Then, DCs were stimulated with lipopolysaccharide (LPS; 1 mg/mL; Sigma-Aldrich) and after 24 hours, production of TNFa and IL-12 was measured in culture supernatants by ELISA. The role of IL-10 was assessed by preincubating MCM with rat anti-human IL-10 monoclonal antibody (Bioscience) or control isotype (BD-Pharmingen; 1 mg/mL) before their addition to DC cultures.
Mixed leukocyte reaction
Mixed lymphocyte reactions (MLR) were carried out by stimulating in 96-well plates nonadherent (CD14 À ) cells (2 Â 
ELISA
Human or murine TGFb1, MCP-1, IL-10, VEGF, TNFa, IL-12, and IFNg from tumor homogenates, serum, or supernatants of DC, NK, or T-cell cultures were measured by ELISA kits (BD Bioscencies) following the manufacturer instructions.
RT-PCR
Monocytes and DC (1 Â 10 5 /200 mL per well) were cultured for 24 hours in 96-well plates in RPMI with DMEM, MCM, or TGFb1-MCM (proportion 1:1). Total RNA extraction from cultures and real-time PCR were carried out as described (19) using specific primers for each gene (Table 1) . Results were normalized according to b-actin. The amount of each transcript was expressed by the formula:
Treatment of tumor-bearing mice with P144
Inhibition of TGFb1 effect on melanoma progression was determined in 6-to 8-week-old female, athymic, nudeFoxn1 nu and in C57BL/6 mice (Harlan). They were maintained in specific pathogen-free conditions and treated according to guidelines of our institution after study approval by the review committee. A375 cells (10 6 ) were injected subcutaneously into the right flank of athymic nude mice and when the tumor diameter reached 5 mm, animals were treated intraperitoneally with P144 (100 mg per mouse) or vehicle (PBS) daily during 21 days. Tumor size was monitored and animals were sacrificed when tumors reached 15 mm. Tumor volume (V) was calculated as follows: 2 , where a and b are the longest and shortest tumor diameters, respectively. C57BL/6 mice were injected intradermally with 10 5 B16-OVA cells and when the tumor diameter reached 5 mm (day 0), they received an intratumor injection of OVA (500 mg), poly(I:C) (50 mg), and agonistic anti-CD40 antibodies (50 mg). On days 2 and 4, they were injected only with poly(I:C) and anti-CD40. P144 (100 mg per mouse) or vehicle was administered daily intraperitoneally from day 0 to day 7. At day 7, they were sacrificed for immunologic assays.
Immunohistochemical analysis of tumors
A375 tumor-bearing athymic mice, treated daily with P144 or vehicle, were sacrificed after 8 days of treatment. Tumors were resected and macrophage infiltrate was studied by immunohistochemical analysis. Tumor sections were incubated for 2 hours with rat anti-F4/80 antibody (1:400; eBiosciences) at 4 C overnight, followed by incubation with 1:200 horseradish peroxidase-conjugated rabbit anti-rat IgG antibody (DakoCytomation) during 30 minutes. Finally, peroxidase activity was visualized using DAB þ Chromogen (DakoCytomation) as a substrate and sections were counterstained with Harris hematoxylin. Macrophage infiltrate was measured by counting the number of pixels corresponding with immunostained cells from digital images using the Adobe Photoshop CS3 program as described (20) .
Angiogenesis
Tumor angiogenesis was also analyzed in nude mice by injecting A375 tumor cells (10 6 ) mixed with Matrigel. Seven IFNg production by murine T cells IFNg production by T cells was measured by ELISA after a 2-day stimulation in 96-well plates of splenocytes (4 Â 10 5 ) with the CD8 epitope OVA(257-264; 1 mg/mL).
Statistical analysis
Data were analyzed using the nonparametric Mann-Whitney test with the GraphPad software program. Survival curves of animals treated with different protocols were plotted according to the Kaplan-Meier method and were compared using the log-rank test. Statistical significance was considered when P < 0.05.
Results
TGFb1 increases MCP-1 and IL-10 expression in A375 cells by the cross-talk between Smad, AKT, and MAPK/ ERK signaling pathways
To study the effect of TGFb1 on MCP-1 and IL-10, two known factors associated with melanoma progression, A375 melanoma cells were treated with this cytokine. Although this cell line does not produce TGFb1 in vitro (data not shown), we found that it can be detected both in A375 tumor homogenates (181 AE 77 pg/mg of protein) and in the serum of A375 tumor-bearing athymic mice (13.5 AE 2.3 ng/mL vs. 7.3 ng/mL in control mice). Although MCP-1 was constitutively expressed by A375 cells, the addition of TGFb1 significantly increased its expression after 48 hours of culture (Fig. 1A) . No detectable expression was found in untreated cultures in the presence of IL-10, whereas a clear induction was observed at 24 and 48 hours in the presence of TGFb1 (Fig. 1B) . Research.
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To characterize signaling pathways involved in the induction of these factors, Western blot experiments were carried out to measure phosphorylation of Smad3 as well as AKT and ERK1/2 kinases. It was found that in A375 cells, TGFb1 induced phosphorylation of the canonical pathway molecule Smad3 but no increase in phosphorylated AKT and ERK kinases over basal constitutive levels was observed (Fig. 1C) . However, by using specific inhibitors of Smad3 (SIS3), PI3K/AKT (LY294002), and MAPK/ERK (U0126) during stimulation experiments, it was found that MCP-1 production was dependent on all 3 molecules whereas IL-10 production depended on Smad3 and MAPK/ERK-related pathways (Fig. 1D) .
TGFb1 enhances MCP-1-mediated monocyte migration
Because TGFb1 increased the production of MCP-1 in A375 cells, we tested whether MCM from A375 cell cultures could enhance monocyte migration. In vitro Transwell experiments showed that TGFb1-MCM from A375 cells had a higher chemoattractive activity on monocytes than that observed with MCM from untreated A375 cells or complete medium (DMEM), an MCP-1-dependent effect ( Fig. 2A) . To evaluate the relevance of an increase in intratumor monocyte infiltration mediated by TGFb1, we measured the expression of VEGF and bFGF in monocytes, two essential factors involved in the progression of melanoma. Interestingly, MCM and TGFb1-MCM induced a similar increase in mRNA expression of both proangiogenic factors (Fig. 2B and C) . Moreover, culture supernatants from untreated or TGFb1-stimulated A375 cells increased the expression of TGFb1 mRNA in monocytes (Fig. 2D) . Thus, although TGFb1 does not directly enhance the ability of monocytes to produce angiogenic factors, it may enhance the proangiogenic environment by increasing the number of infiltrating monocytes, a similar phenomenon as that described for smooth muscle cells (22, 23) .
Inhibition of DC functions by TGFb1-induced IL-10
Although TGFb1-induced IL-10 may have an autocrine stimulatory effect on melanoma cells by increasing their proliferation (24) , it may also behave as a suppressor factor, A B C D Figure 2 . Effect of melanoma conditioned medium from TGFb1-treated A375 cultures on monocytes. A, monocyte migration in the presence of culture medium (CM), MCM, or TGFb1-MCM from A375 cells was studied using Transwell chambers (n ¼ 6 per group) after 6 hours of incubation. In some cases, antihuman MCP-1 or control antibodies were added. B-D, mRNA expression of VEGF, bFGF, and TGFb1 in monocytes cultured during 1 day in the presence of CM, MCM, or TGFb1-MCM.
Results are expressed as the mean þ SEM. *, P < 0.05; **, P < 0.01. One representative experiment of 2 independent experiments is shown.
mainly for antigen-presenting cells. We thus measured the effect that the addition of TGFb1 to tumor cells had on the activation of DCs, a cell population that links innate and adaptive immunity and activates antitumor immunity. An inhibition on LPS-induced TNFa and IL-12 production was observed after pretreatment of DCs with MCM, which was stronger when using TGFb1-MCM, as compared with culture medium (Fig. 3A) . The inhibitory effect of TGFb1-MCM was restored by anti-IL-10 blocking antibodies, confirming the important role of IL-10 as a suppressive factor in TGFb1-MCM.
Similarly, TGFb1-MCM induced upregulation of immunosuppressive molecules such as enzymes COX-2 and IDO (indoleamine-2,3-dioxygenase) and the membrane molecule PD-L1 (Fig. 3B) . In this case, upregulation of COX2 and PD-L1 was dependent on IL-10 whereas IDO expression depended on other TGFb1-induced unknown factors.
We finally studied the ability of these DCs to activate T lymphocytes. Although DCs treated with MCM, with or without TGFb1, had a lower capacity to induce allogeneic T-cell proliferation, a higher inhibition in IFNg production was observed when using DCs treated with TGFb1-MCM Figure 3 . Inhibition of DC functions by melanoma conditioned medium from TGFb1-treated A375 cultures. A, DCs were preincubated in 96-well plates (n ¼ 6 per group) with culture medium (CM), MCM, or TGFb1-MCM from A375 cells for 6 hours and then stimulated for 24 hours with LPS. In some cases, anti-human IL-10 or control antibodies were added. Supernatants were harvested and TNFa and IL-12 levels were measured by ELISA. B, mRNA was obtained from DCs treated as in A and expression of immunosuppressive molecules COX-2, IDO, and PD-L1 was measured by quantitative realtime PCR. C, DCs treated as previously were used to stimulate allogeneic lymphocytes in MLR experiments and proliferation and IFNg production were studied to measure lymphocyte activation. Results are expressed as the mean þ SEM. *, P < 0.05; **, P < 0.01. Representative experiments of 2 or 3 independent experiments are shown. cpm, counts per million.
( Fig. 3C ), in agreement with the lowest levels of IL-12 produced by these DCs.
In vitro and in vivo antitumor effects of the TGF-b1 inhibitor peptide P144
Because TGFb1 plays an important role in the induction of factors relevant for melanoma progression, we analyzed the in vitro and in vivo effects of the TGFb1 inhibitor peptide P144 (17) . In vitro analysis of the classical TGFb1 signaling pathway showed that phosphorylation of Smad3 in A375 cells was decreased after treatment with P144 (Fig. 4A) . Accordingly, TGFb1-induced MCP-1 and IL-10 production in A375 cell cultures was specifically inhibited by this peptide (Fig. 4B) .
Because of the inhibitory effects that P144 had on A375 cells in vitro, we tested this peptide in in vivo tumor models. We first implanted A375 cells subcutaneously in athymic mice, and when tumor diameter reached 5 mm, animals were given P144 injections daily for 3 weeks. TGFb1 is detected both in the serum of these animals and in tumor homogenates, suggesting that this cytokine could be relevant in this in vivo model and susceptible to be considered a target. A significant delay in tumor growth and enhanced survival was observed in those mice treated with P144 (Fig. 5A) . They also had a lower number of tumor-infiltrating macrophages, associated with lower MCP-1 levels (Fig. 5B) . A similar decrease in MCP-1 levels was also observed in the serum ( Supplementary  Fig. S1A ). Moreover, treatment with P144 reduced intratumor VEGF levels ( Supplementary Fig. S1B ) and inhibited tumor angiogenesis, measured as a hemoglobin content (Fig. 5C ) or CD31 staining (Supplementary Fig. S1C ). Finally, in vivo inhibition of MCP-1 with neutralizing antibodies decreased tumor angiogenesis, showing the role of this chemokine in this tumor model (Fig. 5D). Figure 4 . In vitro effects of the TGFb1 inhibitor peptide P144. A, A375 cells were stimulated with TGFb1 for 1 hour in the presence of TGFb1 inhibitor peptide P144 or control peptide P301, and Smad3 phosphorylation was measured by Western blotting. B, A375 cells were stimulated in 96-well plates (n ¼ 6 per group) for 48 hours with TGFb1 in the presence of P144, control peptide P301, or anti-TGFb1 antibodies, and MCP-1 and IL-10 production was measured by ELISA. Representative results of 4 independent experiments are shown. neg, negative; iso, isotype. The immunosuppressive effect of TGFb1 was studied in immunocompetent C57BL/6 mice bearing B16-OVA melanoma tumors, in which the production of TGFb1 (25) and IL-10 (26) has been reported. Although treatment of tumorbearing mice with OVA antigen plus adjuvants poly(I:C) and anti-CD40 delayed tumor growth, combination of this treatment with P144 promoted a higher tumor growth inhibition (Fig. 6A) . This decreased tumor growth was associated with lower intratumor IL-10 (Fig. 6B) . The analysis of innate immunity in the spleen of tumor-bearing mice showed that P144 enhanced the proportion of activated CD86
A B
þ DCs induced by immunotherapy, as well as the activity, measured as IFNg production, of NK cells (Supplementary Fig. S2 ). Moreover, splenic T cells from P144-treated mice produced higher IFNg levels after stimulation with the CD8 þ epitope OVA(257-264) (Fig. 6C ). This enhanced activation of innate and adaptive immunity resulted in higher intratumor levels of IFNg (Fig. 6D) .
Discussion
In the present study, we showed that TGFb1 enhances the production of MCP-1 and IL-10 by A375 melanoma cells, two factors associated with the progression of this malignancy (27) . It has been described that MCP-1 increases tumorassociated monocyte/macrophages, leading to a higher degree of angiogenesis (28) . Moreover, IL-10 has been detected as elevated levels in sera from patients with melanoma and is associated with a shorter survival rate in advanced melanoma patients (16) . However, to our knowledge, the present work is the first to report the induction of MCP-1 and IL-10 by TGFb1 in melanoma cells. Preliminary experiments, carried out using primary tumor lines obtained from patients with metastatic melanoma, have also shown an increase in MCP-1 induction by TGFb1 (E. Feijoo, unpublished results), which confirms the clinical relevance of this finding.
Cross-talk between different signaling pathways has been described to explain the effect of TGFb1 on different factors related to cancer progression. Besides the TGFb1-Smad pathway, several groups have also observed the TGFb1-mediated activation of Smad-independent pathways (29) (30) (31) . We have determined that TGFb1-dependent Smad3 phosphorylation is responsible for the MCP-1 increase and IL-10 induction in A375 cells. Because IL-10 is induced by TGFb1 and it has been previously described that MAP/ERK signaling pathway was implicated in the expression of IL-10 mRNA in A375 cells (32), we hypothesized that this signaling pathway could interact with the Smad3 signaling pathway induced by TGFb1. We have shown that the MAP/ERK1/2 pathway, which is constitutively activated in this melanoma cell line due to the BRAF V600E mutation, a mutation detected in 66% of melanomas (33), is not activated by TGFb1. However, using specific inhibitors, we found that both Smad3 and MAP/ERK1/2 pathways were essential for the expression of IL-10. We have also found that A375 cells show constitutive expression of IL-8, a factor dependent on the MAPK/ERK1/2 pathway but independent on TGFb1 (data not shown). Because PI3K/AKT signaling supports the survival of melanoma cells (34) and has been implicated in the progression of human melanoma (35), we tested the role of this pathway in the production of MCP-1 and IL-10. Even though TGFb1 has no effect on the phosphorylation of AKT, by using a specific inhibitor of PI3K, we observed that MCP-1 production by A375 cells is triggered by this signaling pathway as well as by the Smad3 and MAPK/ ERK signaling pathways. These results suggest the existence of a downstream cross-talk between Smad3, PI3K/AKT, and MAP/ERK1/2 signaling pathways in the expression of MCP-1 and IL-10 in A375 melanoma cells.
Besides the direct effects of TGFb1 on tumor cells, our studies show new indirect mechanisms induced by TGFb1 that facilitate melanoma progression. Indeed, TGFb1-dependent upregulation of MCP-1 resulted in a higher attraction of monocytes, which have been conditioned by tumor cells to A B C D Figure 6 . In vivo effect of TGFb1 inhibitor peptide P144 on B16-OVA tumor growth and immune response. C57BL/6 (n ¼ 6-8 mice per group) bearing subcutaneous B16-OVA tumors were treated with immunotherapy (Adj; OVA plus poly(I:C) and anti-CD40) with or without P144 or left untreated. At day 7, tumor volume (A) and intratumor IL-10 content (B) were evaluated. C, in the same animals, activation of splenic T cells, measured as IFNg production, was analyzed by ELISA after a 2-day stimulation with the CD8 epitope OVA(257-264). D, intratumor IFNg levels in tumor homogenates from mice treated as previously were measured by ELISA. Data are representative of 1 of 2 independent experiments. *, P < 0.05; **, P < 0.01.
produce proangiogenic factors VEGF and bFGF, suggesting that TGFb1 may promote mechanisms that not only favor monocyte infiltration but also condition these cells toward a phenotype that facilitates melanoma progression. There are a number of publications indicating the relevant role of macrophage polarization from M 1 to M 2 in tumor progression (36, 37) . According to this, our results support that monocytes could enhance tumor growth directly by the production of growth factors such as bFGF (38) and VEGF (39) , and, indirectly, by their proangiogenic effect (13) . This possibility seems to be in agreement with a previous work showing that MCP-1 blockage prevented angiogenesis and tumor growth in human malignant melanoma (40) . Moreover, the induction of TGFb1 mRNA in monocytes cultured with A375 melanoma conditioned medium might suggest that tumor-infiltrating monocytes could be a source of this cytokine in patients with melanoma. As it has been described in this work, this TGFb production may constitute a positive loop that further enhances tumor progression. Consistent with the immunosuppressive effect of IL-10, we have shown that TGFb1-MCM induced an IL-10-dependent functional impairment of dendritic cells, characterized by a lower production of proinflammatory factors TNFa and IL-12 and the upregulation of immunoregulatory molecules PDL-1 and COX-2. Moreover, we have also observed that TGFb1-MCM induced other suppressive factors such as IDO in DCs, which may cause their impairment, although in this case, it was independent of the production of IL-10. As a result, a decreased ability to activate IFNg-producing T lymphocytes was observed in DCs cultured with TGFb1-MCM. Thus, these results show that in melanoma, TGFb1 not only acts on DCs through the already described direct immunosuppressive mechanism (5) but also through indirect pathways mediated by IL-10 and other unknown factors which will enhance the final negative effect on this important cell population.
The multifaceted effect of TGFb1 on tumor progression suggests that inhibition of this cytokine should be considered when planning therapeutic strategies in melanoma patients. Indeed, we have reported that inhibition of this cytokine in combination with immunotherapy had some beneficial effects in a murine melanoma model (41) . Because we found several mechanisms induced by TGFb1 on A375 cells favoring tumor progression, we tested the effect of the TGFb1 inhibitor peptide P144. In vitro assays showed that P144 inhibited TGFb1-induced Smad3 phosphorylation and MCP-1 and IL-10 expression in A375 cells cultures. More important, in vivo administration of P144 in two melanoma models significantly delayed tumor growth. In athymic mice bearing A375 tumors, P144 treatment decreased macrophage infiltrate, intratumor MCP-1, and VEGF production as well as tumor angiogenesis, reinforcing the role of TGFb1 and MCP-1 on this tumor growth mechanism. Moreover, in immunocompetent mice, P144 downregulated intratumor IL-10 expression, associated with stronger innate and adaptive immunity. These data show new roles of TGFb1 in the progression of melanoma, such as those responsible for the induction of MCP-1 and IL-10. They suggest that its inhibition in combination with other therapies could be indicated in patients with metastatic melanoma in accordance with recently published data showing that inhibition of TGFb1 enhances the efficacy of immunotherapy (42) (43) (44) .
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